Abstracts tagged "pain management and safety"

Abstract Number: 1367 • 2018 ACR/ARHP Annual Meeting
Efficacy of Intra-Articular Cntx-4975 for Knee OA Pain Varies with Radiographic Presence of OA in the Opposite Knee
Randall Stevens¹, James Campbell¹, Kimberly Guedes¹, Robin Burges¹, Valerie Smith² and Peter Hanson¹, ¹Centrexion Therapeutics, Boston, MA, ²Premier Research, Durham, NC
Background/Purpose: Nearly 60% of patients with knee OA have unilateral OA; most of those patients develop bilateral OA. CNTX-4975 is a highly purified, synthetic trans-capsaicin…
Abstract Number: 1982 • 2016 ACR/ARHP Annual Meeting
Comparative Safety of Long-Acting Opioids for Non-Cancer Pain
Cecilia P. Chung¹, William Dupont², Katherine Murray¹, Kathi Hall³, C. Michael Stein¹ and Wayne Ray³, ¹Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Biostatistics, Vanderbilt University Medical Center, Nashville, TN, ³Health Policy, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Methods: Results: Conclusion:
Abstract Number: 2443 • 2014 ACR/ARHP Annual Meeting
A New Meta-Analysis on Safety of Ketoprofen Vs Ibuprofen and Diclofenac: Risk and Benefit of Nsaids Beyond Efficacy Meta-Analysis
P. Sarzi-Puttini¹, F. Atzeni¹, Luigi Lanata², Alessandra Monguzzi² and Michela Bagnasco², ¹Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, ²Medical Department, Dompé SpA, Milan, Italy
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for management of mild-to-moderate pain, chronic inflammatory and degenerative joint diseases. Among NSAIDs, ketoprofen, ibuprofen and diclofenac…
Abstract Number: 243 • 2014 ACR/ARHP Annual Meeting
Safety of Solumatrix Diclofenac in Adults with Osteoarthritis: Results of a 12-Month, Phase 3 Study
Roy Altman¹, Allan Gibofsky², Marc C. Hochberg³, Byron Cryer⁴, Alan J. Kivitz⁵, Vibeke Strand⁶, Olaolu Imasogie⁷ and Clarence Young⁸, ¹University of California–Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine and Public Health, Hospital for Special Surgery, New York, NY, ³Division of Rheumatology & Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Stanford University, Palo Alto, CA, ⁷Iroko Pharmaceuticals LLC, Philadelphia, PA, ⁸150 Rouse Boulevard, Iroko Pharmaceuticals, LLC, Phila, PA
Background/Purpose: Osteoarthritis (OA) is a frequent cause of disability in adults. NSAIDs such as diclofenac are often prescribed to treat OA pain. However, NSAIDs…
Abstract Number: 2149 • 2013 ACR/ARHP Annual Meeting
Safety Of Lower-Dose Diclofenac Submicron Particle Capsules Dosed Up To 12 Weeks In Patients With Osteoarthritis
Clarence Young¹ and Marc C. Hochberg², ¹Iroko Pharmaceuticals, Philadelphia, PA, ²Medicine, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Osteoarthritis (OA) is the most common cause of disability in the US and is frequently managed with non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs, including diclofenac,…
Abstract Number: 1095 • 2013 ACR/ARHP Annual Meeting
Pooled Safety Data From Randomized, Controlled Trials Of Diclofenac Sodium Topical Gel 1% In Subjects With Acute Pain
Roy D. Altman¹, Helmut Pabst², Hans-Georg Predel³, Bruno Giannetti⁴, Ian Burnett⁵, Morris Gold⁶ and Evan F. Ekman⁷, ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²Independent Physician, Gilching, Germany, ³German Sports University, Cologne, Germany, ⁴CRM clinical trials GmbH, Rheinbach, Germany, ⁵Novartis Consumer Health, Nyon, Switzerland, ⁶Novartis Consumer Health, Parsippany, NJ, ⁷Southern Orthopaedic Sports Medicine, Columbia, SC
Background/Purpose: Diclofenac sodium topical gel (DSG) 1% is clinically proven to be effective and well-tolerated for treatment of osteoarthritis pain and could be appropriate to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].